Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function

Journal of Nuclear Medicine

Volumn 49, Issue 2, 2008, Pages 225-233

  Nagahara, Daigo ^a   Nakata, Tomoaki ^a   Hashimoto, Akiyoshi ^a   Wakabayashi, Takeru ^a   Kyuma, Michifumi ^a   Noda, Ryosuke ^a   Shimoshige, Shinya ^a   Uno, Kikuya ^a   Tsuchihashi, Kazufumi ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brain natriuretic peptide; Implantable cardioverter defibrillator; Lethal arrhythmias; Metaiodobenzylguanidine imaging; Sudden cardiac death

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SOTALOL;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DEFIBRILLATOR; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

3-IODOBENZYLGUANIDINE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT SELECTION; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 38949094149     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.042564     Document Type: Article

References (31)

1. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS Studies. Antiarrhythmics vs Implantable Defibrillator Study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-2078.
2. Moss AJ, Zareba W, Hall WJ, et al., for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
3. Merlet P, Valette H, Dubois-Randé JL, et al. Prognostic value of cardiac MIBG imaging in patients with heart failure. J Nucl Med. 1992;33:471-477.
4. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and non-failing hearts. J Nucl Cardiol. 1998;5:579-590.
5. Wakabayashi T, Nakata T, Hashimoto A, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med. 2001;42:1757-1767.
6. Nakata T, Wakabayashi T, Kyuma M, et al. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail. 2003;9:113-121.
7. Kyuma M, Nakata T, Hashimoto A, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation and non-cardiac disorders in patients with heart failure. J Nucl Med. 2004;45:155-163.
8. Suwa M, Otake Y, Moriguchi A, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J. 1997;133:353-358.
9. 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med. 1999;40:217-223.
10. 123I-MIBG scintigraphic study. J Nucl Med. 2000;41:845-851.
11. Kasama S, Toyama T, Kumakura H, et al. Addition of valsartan to an angiotensinconverting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med. 2003;44:884-890.
12. Kasama S, Toyama T, Kumakura H, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2003;41:574-581.
13. Nakata T, Wakabayashi T, Kyuma K, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term prognostic efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging. 2005;32:186-194.
14. Gregoratos G, Cheitlin MD, Conill A, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: executive summary - a report of the ACC/AHA task force on practice guidelines (committee on pacemaker implantation). Circulation. 1998;97:1325-1335.
15. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death: experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation. 1992;85:I77-I91.
16. 123I] metaiodobenzylguanidine scans in patients with ventricular tachycardia and a "clinically normal" heart. Br Heart J. 1993;69:6-13.
17. Calkins H, Allman K, Bolling S. Correlation between scintigraphic evidence of regional sympathetic neuronal dysfunction and ventricular refractoriness in the human heart. Circulation. 1993;88:172-179.
18. Galinier M, Pathak A, Fourcade J, et al. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J. 2000;21:475-482.
19. La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation. 2003;107:565-570.
20. Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121-131.
21. Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med. 1994;330:235-241.
22. Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverterdefibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol. 2006;48:112-121.
23. Shusterman V, Goldberg A, London B. Upsurge in T-wave alternans and nonalternating repolarization instability precedes spontaneous initiation of ventricular tachyarrhythmias in humans. Circulation. 2006;113:2880-2887.
24. Kaufman ES, Mackall JA, Julka B, Drabek C, Rosenbaum DS. Influence of heart rate and sympathetic stimulation on arrhythmogenic T wave alternans. Am J Physiol Heart Circ Physiol. 2000;279:H1248-H1255.
25. Armoundas AA, Albert CM, Cohen RJ, Mela T. Utility of implantable/ cardioverter defibrillator electrocardiograms to estimate repolarization alternans preceding a tachyarrhythmic event. J Cardiovasc Electrophysiol. 2004;15:594-597.
26. Verrier RL, Nearing BD, Kwaku KF. Noninvasive sudden death risk stratification by ambulatory ECG-based T wave alternans analysis: evidence and methodological guidelines. Ann Noninvasive Electrocardiol. 2005;10:110-120.
27. Nakata T, Wakabayashi T, Nagahara D. Assessment of cardiac innervation in heart failure and lethal arrhythmias: Therapeutic and prognostic implications. Curr Cardiol Rev. 2005;1:29-36.
28. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93:1667-1676.
29. Miyazaki T, Zipes DP. Presynaptic modulation of efferent sympathetic and vagal neurotransmission in the canine heart by hypoxia, high K+, low pH, and adenosine: possible relevance to ischemia-induced denervation. Circ Res. 1990;66:289-301.
30. Inoue H, Zipes DP. Result of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation. 1987;75:877-887.
31. Sheldon R, Connolly S, Krahn A, Roberts R, Gent M, Gardner M. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy. The Canadian Implantable Defibrillator Study. Circulation. 2000;101:1660-1664.